Daniel L. Mulkerin, MD Print Friendly Page
Faculty, University of Wisconsin School of Medicine and Public HealthDaniel Mulkerin, MD graduated from Jefferson Medical College. He then completed residency in Internal Medicine and Fellowship in Medical Oncology at the University of Wisconsin Hospital and Clinics. Dr. Mulkerin joined the UW Medical School faculty in 1999 and is currently an Assistant Professor in the Department of Medicine, Section of Medical Oncology. His clinical expertise is in the treatment of gastrointestinal malignancies, including liver and pancreas esophageal, stomach, biliary, colon, rectal and anal cancers. He is actively involved in the development of new therapies for patients with these diseases. Dr. Mulkerin also serves as Regional Director of the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center regional cancer center network, which includes affiliate sites in eight communities within Wisconsin and Illinois.
Specialties
UW Health Clinics
Hospital Affiliation(s)
University of Wisconsin Hospital and Clinics (primary)
Languages Spoken
| English |
| Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000. |
UW School of Medicine and Public Health
| Department of Medicine |
Professional Certifications and Education
| Board Certification |
Medical Oncology
Internal Medicine |
| Fellowship |
University of Wisconsin Hospital and Clinics, Madison, WI
|
| Residency |
University of Wisconsin Hospital and Clinics, Madison, WI
|
| Internship |
University of Wisconsin Hospital and Clinics, Madison, WI
|
| Medical School |
Jefferson Medical College, Philadelphia, PA, 1992
|
Awards/Honors
PubMed Articles
-
Shibata SI Chung V Synold TW Longmate JA Suttle AB Ottesen LH Lenz HJ Kummar S Harvey RD Hamilton AL O'Neil BH Sarantopoulos J Lorusso P Rudek MA Dowlati A Mulkerin DL Belani CP Gandhi L Lau SC Ivy SP Newman EM .
Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. Clin Cancer Res. 2013 Jun 5;
[PubMed ID: 23653147]
-
Loconte NK Holen KD Schelman WR Mulkerin DL Deming DA Hernan HR Traynor AM Goggins T Groteluschen D Oettel K Robinson E Lubner SJ .
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs. 2012 Dec 21;
[PubMed ID: 23263993]
-
Leal TB Remick SC Takimoto CH Ramanathan RK Davies A Egorin MJ Hamilton A LoRusso PA Shibata S Lenz HJ Mier J Sarantopoulos J Mani S Wright JJ Ivy SP Neuwirth R von Moltke L Venkatakrishnan K Mulkerin D .
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol. 2011 Dec;68(6):1439-47
[PubMed ID: 21479634]
-
Mohammed TA Holen KD Jaskula-Sztul R Mulkerin D Lubner SJ Schelman WR Eickhoff J Chen H Loconte NK .
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist. 2011;16(6):835-43
[PubMed ID: 21632454]
-
Lubner SJ Kunnimalaiyaan M Holen KD Ning L Ndiaye M Loconte NK Mulkerin DL Schelman WR Chen H .
A preclinical and clinical study of lithium in low-grade neuroendocrine tumors. Oncologist. 2011;16(4):452-7
[PubMed ID: 21393344]
-
Leal T Tevaarwerk A Love R Stewart J Binkley N Eickhoff J Parrot B Mulkerin D .
Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer. Clin Breast Cancer. 2010 Dec 1;10(6):471-6
[PubMed ID: 21147691]
-
Lubner SJ Loconte NK Holen KD Schelman W Thomas JP Jumonville A Eickhoff JC Seo S Mulkerin DL .
A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2010 Jul;9(3):157-61
[PubMed ID: 20643620]
-
Attia S Morgan-Meadows S Holen KD Bailey HH Eickhoff JC Schelman WR Traynor AM Mulkerin DL Campbell TC McFarland TA Huie MS Cleary JF Tevaarwerk AJ Alberti DB Wilding G Liu G .
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemother Pharmacol. 2009 Jun;64(1):45-51
[PubMed ID: 18841362]
-
Attia S Holen KD Thomas JP Richie K Dzelak T Teeter K Warren D Bilger A Fine J Eickhoff J Drinkwater N Mulkerin D Morgan-Meadows S .
Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma. Clin Adv Hematol Oncol. 2008 Jan;6(1):44-54
[PubMed ID: 18322441]
-
Bailey HH Alberti DB Thomas JP Mulkerin DL Binger KA Gottardis MM Martell RE Wilding G .
Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. Clin Cancer Res. 2007 Jun 15;13(12):3623-9
[PubMed ID: 17510207]
-
Morgan-Meadows S Mulkerin D Berlin JD Kim K Bailey H Saphner T Jumonville A Hansen R Ahuja H McFarland T Thomas JP .
A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. Oncology. 2005;69(2):130-4
[PubMed ID: 16118509]
-
Couch LS Groteluschen DL Stewart JA Mulkerin DL .
Capecitabine-related neurotoxicity presenting as trismus. Clin Colorectal Cancer. 2003 Aug;3(2):121-3
[PubMed ID: 12952569]
-
Morgan-Meadows S Thomas JP Mulkerin D Berlin JD Bailey H Binger K Volkman J Alberti D Feierabend C Marrocha R Arzoomanian RZ Wilding G .
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy. Invest New Drugs. 2002 Nov;20(4):377-82
[PubMed ID: 12448654]
-
Meadows SM Mulkerin D Berlin J Bailey H Kolesar J Warren D Thomas JP .
Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. Int J Gastrointest Cancer. 2002;32(2-3):125-8
[PubMed ID: 12794248]
